- Combined injectable contraceptive
Combined Injectable Contraceptive Background Birth control type Hormonal First use about 1980 Failure rates (first year) Perfect use 0-0.2% Typical use ? Usage Duration effect 1 month User reminders ? Advantages and disadvantages STD protection No Benefits Especially good if poor pill compliance.
Combined injectable contraceptive (CIC) monthly injection of progesterone and estradiol taken to inhibit fertility. Brand names include Cyclofem, Novafem, Mesigyna, Lunelle and Cyclo-Provera.
DMPA is a different injectable contraceptive, containing just a progestin, given every three months.
- October 5, 2000, Pharmacia received FDA approval for Lunelle Monthly Contraceptive Injection.
- April 2003, Pharmacia acquired by Pfizer (makers of Depo-Provera (DMPA)).
- October 2003, Lunelle was discontinued in the U.S.
Use and packaging
The most prominent side effects are menstrual irregularities during the first 3 to 6 months of use.
- Lunelle contains medroxyprogesterone acetate (MPA) 25 mg plus estradiol cypionate (E2C) 5 mg.
- Cyclofem contains depomedroxy-progesterone acetate (DMPA) 25 mg and estradiol cypionate 5 mg.
- Mesigyna contains norethisterone enanthate (NET EN) 50 mg and estradiol valerate 5 mg.
- Deladroxate contains dihydroxy-progesterone acetophenide 150 mg and estradiol enanthate 10 mg.
- ^ a b c d e f "FDA Approves Combined Monthly Injectable Contraceptive" ([dead link]). Contraception Report 12 (3). 2001. http://www.contraceptiononline.org/contrareport/article01.cfm?art=176.
Birth control methods (G02B, G03A) Comparison Behavioral Barrier or
Anti-estrogenOrmeloxifene (Centchroman) Post-intercourse Intrauterine device Abortion Sterilization Program for Appropriate Technology in Health (PATH) Key peopleChristopher Elias, CEO Projects Products This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.